Robin L. Washington is the Executive Vice President and Chief Financial Officer of Gilead Sciences, Inc. In this role, she oversees the Investor Relations, Global Finance and Information Technology organizations. Gilead is a Fortune 500 research-based biopharmaceutical company that discovers, develops and commercializes innovative medicines in areas of unmet medical need. Gilead’s portfolio of products and pipeline include treatments for HIV/AIDS, liver diseases, cancer, inflammation and respiratory diseases, and products for cardiovascular conditions.
Prior to Gilead, Washington was the Chief Financial Officer of Hyperion Solutions Inc., an enterprise software company providing business performance management solutions for global enterprises.
In 2016, Washington was recognized as the #1 CFO in Biotechnology by Institutional Investor Magazine and in 2014, she was recognized by The Wall Street Journal as one of the Top 10 Performing CFOs (#6) in the S&P 500.
Washington is currently a member of the Board of Directors of Alphabet, Honeywell International and Salesforce.com. She is also a member of The Council on Foreign Relations.
Washington holds a Bachelor’s in Business Administration from the University of Michigan and an MBA from Pepperdine University.
